Topic: Promising new regimens or studies of uncertain value?
Diacon et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-93.
Presenter: Jurgens Peters, London School of Hygiene and Tropical Medicine
Chair: Patrick Phillips, MRC Clinical Trials Unit
Time: 1:00-1.50 pm, 31 January 2013
Venue: Room 402, MRC Clinical Trials Unit, Aviation House, 125 Kingsway
Directions: See http://www.ctu.mrc.ac.uk/about_us/contact_details.aspx. The entrance is opposite Holborn tube station and looks like the entrance to a church building.
* External attendees will need to wait at reception and be taken to the meeting room. If you plan to attend, please contact Patrick Phillips on firstname.lastname@example.org so that reception know who is expected. *
We urgently need better drugs for TB. This would allow for shorter first line therapy and treatment for drug resistant TB this is safer and more effective with patients experiencing fewer unpleasant side effects.
This paper describes interesting data on novel drugs and combinations that seem to exhibit good ‘early bactericidal activity’. These include a regimen that might work for MDR-TB.
With the FDA advisory committee recently recommending limited approval of Bedaquiline for MDR-TB on the basis of culture conversion data from Phase II studies, the use of surrogate outcomes is topical.
Join us to discuss the design and evaluation of new TB regimens, the value of surrogate outcomes, and the future of TB therapy.
The paper is available here.